Abstract Details

Title Comparisons of Five Year Treatment Patterns in the NARCOMS Registry

Topic MS and Related Diseases

Presentation(s) P04 - (-)

Poster/Presentation
Number 137

Objective

Background BACKGROUND: The North American Research Committee on Multiple Sclerosis (NARCOMS) collects disease modifying therapy (DMT) information/outcome measures from MS participants. Presumably those on a continuous DMT have more adequately controlled disease than those who switch therapy.

Design/Methods DESIGN/METHODS: Participants with at least one completed semiannual survey each year for 5 consecutive years (2006-2010) were selected and categorized by their DMT use: interferon beta-1a IM, interferon beta-1a SC, interferon beta 1b, glatiramer acetate, or other DMTs. Progression was defined an increase in Patient Determined Disease Steps (PDDS) score in 2 subsequent surveys after baseline. Analyses determined the probabilities of transitions across PDDS level by DMT and pattern of DMT use.

Results RESULTS: Of the 6,127 participants: 2335 (38.1%) had no DMTs or classifiable pattern of DMT use (ND); 1,712 (27.9%) were on a continuous, single DMT (CD); 1,299 (21.2%) switched DMTs (SD) and 781 (12.7%) added or discontinued DMT (AD+DD). The four groups differed (p<0.0001) on gender, age, and employment. Median baseline PDDS (IQR) was 2 (1-4) (Mild Disability) for the SD group compared to all other change groups with a median 4 (2-5) (Early Cane). The SD group was more likely to transition to a higher PDDS score at the following 6-month interval and a higher proportion in the SD group progressed compared to CD group(43.7% vs. 30.0%).

Conclusions CONCLUSIONS: Those who remain on the same DMT report a lower increase in PDDS than those who switched DMTs. While all groups exhibited some disease progression over the 5-year period, those who switched experienced more progression as switching is likely a sign of inadequate disease control. In observational studies there appears to be an obvious relationship between DMT usage and disease process.

Authors/Disclosures
Amber Salter, PhD (UT Southwestern Medical Center) PRESENTER	Dr. Salter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gryphon Bio. Dr. Salter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abata Therapeutics. Dr. Salter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sora Neuroscience. Dr. Salter has stock in Owl Therapeutics. The institution of Dr. Salter has received research support from National Multiple Sclerosis Society. The institution of Dr. Salter has received research support from Department of Defense Congressionally Directed Medical Research Program. The institution of Dr. Salter has received research support from Consortium of Multiple Sclerosis Centers.
	No disclosure on file
	No disclosure on file
Stephen J. Glenski, PharmD	No disclosure on file
Scott Kolodny, MD (Teva Pharmaceuticals)	No disclosure on file
	No disclosure on file
Stacey Cofield	No disclosure on file
Gary R. Cutter, PhD (University of Alabama At Birmingham)	Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for onsulting or Advisory Boards: Alexion, Antisense Therapeutics/Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Genzyme, Genentech, Immunic, Klein-Buendel Incorporated, Kyverna Therapeutics, Inc. , Linical, Merck/Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, Roche, SAB Biotherapeutics, Sapience Therapeutics, Scott&Scott LLP, Tenmile.. Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Argenx, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiamedicaTherapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.

��ɫ��

��ɫ��